ECSP12011983A - Moduladores alostéricos positivos de receptores m1 de la quinolina amida - Google Patents

Moduladores alostéricos positivos de receptores m1 de la quinolina amida

Info

Publication number
ECSP12011983A
ECSP12011983A ECSP12011983A ECSP12011983A EC SP12011983 A ECSP12011983 A EC SP12011983A EC SP12011983 A ECSP12011983 A EC SP12011983A EC SP12011983 A ECSP12011983 A EC SP12011983A
Authority
EC
Ecuador
Prior art keywords
receptors
quinoline
positive allosteric
allosteric modulators
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Scott D Kuduk
Zhi-Qiang Yang
Kelly-Ann Schlegel
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP12011983A publication Critical patent/ECSP12011983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a compuestos de quinolina amida de la fórmula (I) (I)que son moduladores alostéricos positivos de los receptores M1 y que resultan de utilidad en el tratamiento de enfermedades en las cuales está involucrado el receptor M1, tales como mal de Alzheimer, esquizofrenia, trastornos del dolor o trastornos del sueño. La invención también se refiere a composiciones farmacéuticas que comprenden los compuestos, y al uso de los compuestos y las composiciones en el tratamiento de enfermedades mediadas por el receptor M1.
ECSP12011983 2009-12-17 2012-06-19 Moduladores alostéricos positivos de receptores m1 de la quinolina amida ECSP12011983A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28753509P 2009-12-17 2009-12-17

Publications (1)

Publication Number Publication Date
ECSP12011983A true ECSP12011983A (es) 2012-07-31

Family

ID=44305688

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011983 ECSP12011983A (es) 2009-12-17 2012-06-19 Moduladores alostéricos positivos de receptores m1 de la quinolina amida

Country Status (41)

Country Link
US (2) US9199939B2 (es)
EP (1) EP2512243B1 (es)
JP (1) JP5651708B2 (es)
KR (1) KR101494059B1 (es)
CN (1) CN102651970B (es)
AR (1) AR079510A1 (es)
AU (1) AU2010340142B2 (es)
BR (1) BR112012014180A2 (es)
CA (1) CA2782347C (es)
CL (1) CL2012001605A1 (es)
CO (1) CO6551729A2 (es)
CR (1) CR20120327A (es)
CY (1) CY1117726T1 (es)
DK (1) DK2512243T3 (es)
DO (1) DOP2012000167A (es)
EA (1) EA022494B1 (es)
EC (1) ECSP12011983A (es)
ES (1) ES2575154T3 (es)
GE (1) GEP201606506B (es)
GT (1) GT201200201A (es)
HK (1) HK1170122A1 (es)
HN (1) HN2012001265A (es)
HR (1) HRP20160574T1 (es)
HU (1) HUE029734T2 (es)
IL (1) IL220130A0 (es)
MA (1) MA33920B1 (es)
ME (1) ME02421B (es)
MX (1) MX336774B (es)
NI (1) NI201200107A (es)
NZ (1) NZ600674A (es)
PE (1) PE20121613A1 (es)
PL (1) PL2512243T3 (es)
PT (1) PT2512243E (es)
RS (1) RS54798B1 (es)
SG (1) SG181719A1 (es)
SI (1) SI2512243T1 (es)
TN (1) TN2012000231A1 (es)
TW (1) TWI412525B (es)
UA (1) UA106406C2 (es)
WO (1) WO2011084368A1 (es)
ZA (1) ZA201204313B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
BR112012029237A2 (pt) 2010-05-17 2016-11-29 Envivo Pharmaceuticals Inc forma cristalina de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida monohidratado
WO2011159554A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
EP2709621B1 (en) * 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
MX2016001942A (es) 2013-09-27 2016-06-02 Hoffmann La Roche Derivados de indol e indazol.
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
RU2016132858A (ru) * 2014-01-22 2018-03-02 Ф. Хоффманн-Ля Рош Аг Производные фторнафтила
EP3156397B1 (en) * 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016198342A1 (de) 2015-06-09 2016-12-15 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
MX2018002821A (es) * 2015-09-10 2018-09-12 Suven Life Sciences Ltd Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
WO2017099969A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Tetrahydroquinoxaline m1 receptor positive allosteric modulators
MX2018009952A (es) * 2016-02-16 2018-11-29 Univ Vanderbilt Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1.
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
JP2019524722A (ja) 2016-07-11 2019-09-05 バイエル・ファルマ・アクティエンゲゼルシャフト ７−置換１−ピリジル−ナフチリジン−３−カルボン酸アミドおよびその使用
RS60875B1 (sr) * 2016-09-02 2020-11-30 Suven Life Sciences Ltd Pozitivni alosterni modulatori muskarinskog m1 receptora
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
WO2018063552A1 (en) 2016-09-30 2018-04-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
PL3643718T3 (pl) * 2017-06-20 2024-01-22 Takeda Pharmaceutical Company Limited Związek heterocykliczny i jego zastosowanie jako dodatniego modulatora allosterycznego względem cholinergicznego receptora muskarynowego m1
CA3068209A1 (en) * 2017-06-20 2018-12-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2020004339A (es) * 2017-10-27 2020-08-03 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico.
WO2020067456A1 (ja) 2018-09-28 2020-04-02 武田薬品工業株式会社 複素環化合物
EP3858823A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC COMPOUND
JP7140915B2 (ja) 2018-10-17 2022-09-21 スヴェン・ライフ・サイエンシーズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーターとしてのピロロ－ピリダジン誘導体
US12065433B2 (en) 2018-10-24 2024-08-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
WO2002018344A1 (fr) * 2000-08-29 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives esteriques ou amidiques
EP1596867A4 (en) 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH ECTOPIC ACTIVATOR OF M1 MUSCARINIC RECEPTOR
EP1601357A4 (en) * 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
ATE457309T1 (de) 2003-12-23 2010-02-15 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
US20070185090A1 (en) * 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
CN101321733A (zh) * 2005-12-05 2008-12-10 默克公司 喹诺酮m1受体阳性变构调节剂
CA2631917A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators
PE20091036A1 (es) * 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
AU2009225883A1 (en) * 2008-03-21 2009-09-24 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
EA019098B1 (ru) 2008-11-20 2014-01-30 Мерк Шарп Энд Домэ Корп. Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
AU2010216263A1 (en) 2009-02-23 2011-07-14 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
WO2010123716A1 (en) 2009-04-20 2010-10-28 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
KR101651312B1 (ko) 2009-08-31 2016-08-25 머크 샤프 앤드 돔 코포레이션 피라닐 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제
WO2011049731A1 (en) 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
EP2501231B1 (en) 2009-11-20 2016-12-21 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
EP2512245B1 (en) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
WO2011084371A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
WO2011159553A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
WO2011159554A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
EP2709621B1 (en) 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
HRP20160574T1 (hr) 2016-06-17
PL2512243T3 (pl) 2016-09-30
ME02421B (me) 2016-09-20
JP5651708B2 (ja) 2015-01-14
GEP201606506B (en) 2016-07-11
NI201200107A (es) 2012-10-30
HK1170122A1 (zh) 2013-02-22
DOP2012000167A (es) 2012-12-31
CL2012001605A1 (es) 2012-10-05
MA33920B1 (fr) 2013-01-02
SI2512243T1 (sl) 2016-07-29
JP2013514358A (ja) 2013-04-25
AU2010340142B2 (en) 2014-05-08
DK2512243T3 (en) 2016-07-25
RS54798B1 (sr) 2016-10-31
ES2575154T3 (es) 2016-06-24
CA2782347C (en) 2014-09-23
CR20120327A (es) 2012-07-30
NZ600674A (en) 2013-05-31
AU2010340142A1 (en) 2012-06-14
IL220130A0 (en) 2012-07-31
KR20120084324A (ko) 2012-07-27
TWI412525B (zh) 2013-10-21
ZA201204313B (en) 2016-01-27
CN102651970A (zh) 2012-08-29
HN2012001265A (es) 2015-09-07
BR112012014180A2 (pt) 2015-09-15
US9199939B2 (en) 2015-12-01
SG181719A1 (en) 2012-07-30
CO6551729A2 (es) 2012-10-31
HUE029734T2 (en) 2017-03-28
AR079510A1 (es) 2012-02-01
UA106406C2 (ru) 2014-08-26
TN2012000231A1 (en) 2013-12-12
MX2012007013A (es) 2012-07-03
EA022494B1 (ru) 2016-01-29
EP2512243A4 (en) 2013-05-29
CN102651970B (zh) 2014-11-12
EP2512243B1 (en) 2016-04-06
CY1117726T1 (el) 2017-05-17
TW201130824A (en) 2011-09-16
EA201290519A1 (ru) 2013-01-30
US20160075656A1 (en) 2016-03-17
KR101494059B1 (ko) 2015-02-16
WO2011084368A1 (en) 2011-07-14
MX336774B (es) 2016-01-28
PT2512243E (pt) 2016-06-08
GT201200201A (es) 2015-05-20
US20120252808A1 (en) 2012-10-04
PE20121613A1 (es) 2012-12-02
CA2782347A1 (en) 2011-07-14
EP2512243A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
ECSP12011983A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
DOP2011000135A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
CO6501188A2 (es) Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
NI201000090A (es) Agonistas novedosos de los receptores de glucocorticoides.
IN2014KN01075A (es)
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
HN2010002403A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
CO6541615A2 (es) Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5
EA201270825A1 (ru) Применение производного эстрогена для производства фармацевтических композиций, пригодных для лечения и/или предотвращения психиатрических заболеваний, и для лечения и предотвращения указанных заболеваний
JO2919B1 (en) Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor
CR20170140A (es) Compuestos de sulfonamida heterocíclica sustituída útiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1)
CU20100110A7 (es) Agonistas novedosos de los receptores de glucocorticoides